1. Inicio
  2. Proyectos y Estudios
  3. open-label, single-arm trial to evaluate the pharmacokinetics and safety of bimekizumab in pediatric study participants from 2 to less than 18 years of age with active juvenile idiopathic arthritis subtypes enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis.

open-label, single-arm trial to evaluate the pharmacokinetics and safety of bimekizumab in pediatric study participants from 2 to less than 18 years of age with active juvenile idiopathic arthritis subtypes enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis.

Datos básicos

ENSAYO CLÍNICO JA0005 HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2025

Documentos

  • No hay documentos

Participantes

Ver todos los Investigadores

Grupos

Financiadores - Promotores

UCB BIOPHARMA SRL

Compartir